Algeta appoints senior vp, Protein Therapeutics

New role created to drive development of Thorium platform

Algeta, a Norwegian company focused on the development of novel targeted cancer therapeutics, has appointed Lars Abrahmsen as senior vp, Protein Therapeutics.

Abrahmsen takes responsibility for the development of Oslo-based Algeta’s Thorium platform and for building and overseeing the preclinical development of a pipeline of alpha-pharmaceutical candidates based on tumour-targeted thorium-227 conjugates.

This builds on the progress made with Alpharadin, an alpha-pharmaceutical being developed in a phase III trial by Algeta and Bayer Schering Pharma for treating bone metastases arising from castration-resistant prostate cancer.

Abrahmsen has joined Algeta from Affibody, a Swedish company developing proprietary targeting molecules for therapeutic and diagnostic purposes, where he held the position of chief scientific officer since 2004. Prior to this he worked for Genentech and Pharmacia, where he established their phage display and antibody cloning capabilities.

You may also like

Regulatory

Anticancer agent – radium-223 chloride

Radiotherapy commonly involves directing beams of radioactive particles at the tumour, or a radioactive source being placed within the body
Research & Development

Algeta wins grant to develop alpha-pharmaceuticals based on Thorium-227

Norwegian firm to create pipeline of cancer-destroying drugs
Research & Development

Algeta to collaborate with Genzyme

To evaluate Thorium-227 conjugated with a novel tumour-targeting antibody
Research & Development

Algeta signs Alpharadin manufacturing deals

Triggers €5m milestone payment from Bayer Schering Pharma
Research & Development

Lindus Health and Quotient Sciences team up to accelerate drug development process

The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials
Research & Development

CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration

Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development

New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research

Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Subscribe now